VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?

VolitionRx (VNRX) shares ripped more than 34% in Wednesday’s pre-market trade after the company announced proof-of-concept data from a blinded validation cohort for the detection of cancer.

The company said that it has developed a new liquid biopsy method, and during a blind validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Retail sentiment on Stocktwits around Volition trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

For updates and corrections, email newsroom[at]stocktwits[dot]com.